• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突眼性甲状腺肿-格雷夫斯-帕里-弗拉亚尼病的眼部变化及眼病治疗方法

Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.

作者信息

Saraci George, Treta Anamaria

机构信息

"Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, County Emergency Hospital Cluj, MD- Senior Doctor - Internal Medicine, PhD Student-Gastroenterology.

出版信息

Maedica (Bucur). 2011 Apr;6(2):146-52.

PMID:22205899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3239395/
Abstract

Basedow-Graves disease is an autoimmune condition with multiple local and systemic aspects. Among these, oculopathy has a major impact on patient's life from both functional and esthetic point of view. Basedow-Graves oculopathy requires an appropriate positive and differential diagnosis using clinical and imagistic approaches. Treatment is always required in moderate or severe forms and it begins with simple general points and continues with medical and surgical therapies. Current article stresses upon the most characteristic clinical signs of thyroidian ophthalmopathy and the required current therapeutic approaches.

摘要

突眼性甲状腺肿(Basedow-Graves病)是一种具有多种局部和全身表现的自身免疫性疾病。其中,眼病从功能和美学角度对患者生活都有重大影响。突眼性甲状腺肿眼病需要采用临床和影像学方法进行适当的肯定性诊断和鉴别诊断。中度或重度形式总是需要治疗,治疗从简单的一般要点开始,接着是药物和手术治疗。本文着重介绍甲状腺眼病最典型的临床体征以及当前所需的治疗方法。

相似文献

1
Ocular changes and approaches of ophthalmopathy in basedow - graves- parry- flajani disease.突眼性甲状腺肿-格雷夫斯-帕里-弗拉亚尼病的眼部变化及眼病治疗方法
Maedica (Bucur). 2011 Apr;6(2):146-52.
2
[Epidemiological, clinical, therapeutic and evolutive aspects of Basedow-Graves disease in the Depatment of Internal Medicine at CHU Aristide Le Dantec, Dakar (Senegal)].[达喀尔(塞内加尔)阿利斯蒂德·勒丹泰克大学医院内科基于格雷夫斯病的流行病学、临床、治疗及演变情况]
Pan Afr Med J. 2016 Sep 14;25:6. doi: 10.11604/pamj.2016.25.6.7868. eCollection 2016.
3
[Titers of antibodies against thyroid membrane antigens in patients with Graves-Basedow disease and progressive infiltrative ophthalmopathy during treatment with glucocorticoids and retro-orbital tissue irradiation].[格雷夫斯-巴塞多氏病合并进行性浸润性眼病患者在接受糖皮质激素和眶后组织照射治疗期间抗甲状腺膜抗原抗体的滴度]
Pol Tyg Lek. 1991;46(43-44):824-6.
4
[Graves-Basedow ophthalmopathy in light of current views].基于当前观点的格雷夫斯-巴塞多眼病
Przegl Lek. 2000;57(6):307-12.
5
[Risk factors for occurrence of ophthalmopathy in the course of Graves-Basedow disease].[格雷夫斯-巴塞多氏病病程中眼部病变发生的危险因素]
Przegl Lek. 2000;57(6):321-3.
6
Extraocular muscle repositioning as the last therapeutic option for a patient with a severe course of Graves' Ophthalmopathy: a case report.眼外肌重新定位术作为Graves眼病严重病程患者的最后治疗选择:一例病例报告
BMC Ophthalmol. 2018 Feb 27;18(1):56. doi: 10.1186/s12886-018-0718-1.
7
[Carl Adolph von Basedow on the on the occasion of the 150th anniversary of the day he died].[卡尔·阿道夫·冯·巴泽多逝世150周年之际]
J Dtsch Dermatol Ges. 2004 Nov;2(11):963-7. doi: 10.1046/j.1439-0353.2004.04078.x.
8
[A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease].[格雷夫斯-巴塞多病病程中甲状腺相关性眼病的一种特殊情况]
Endokrynol Pol. 2006 Sep-Oct;57(5):536-40.
9
[Management of patient with Gaves' orbitopathy].[格雷夫斯眼眶病患者的管理]
Clin Ter. 2012 Nov;163(6):e463-74.
10
Case of Graves' (Parry-Graves-Basedow) Disease in a Woman, aged 69, without Goitre.一名69岁无甲状腺肿的女性格雷夫斯病(帕里-格雷夫斯-巴塞多病)病例。
Proc R Soc Med. 1923;16(Clin Sect):44-5. doi: 10.1177/003591572301600335.

引用本文的文献

1
Ocular surface disease in thyroid eye disease: A narrative review.甲状腺眼病中的眼表面疾病:叙述性综述。
Ocul Surf. 2022 Apr;24:67-73. doi: 10.1016/j.jtos.2022.02.001. Epub 2022 Feb 12.
2
Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.甲状腺相关眼病与生物标志物:现状与未来展望。
Dis Markers. 2018 Mar 15;2018:7010196. doi: 10.1155/2018/7010196. eCollection 2018.
3
Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome).菲利普·E·克莱尔医学博士:对低血糖和葡萄糖反调节的理解以及HAAF(克莱尔综合征)的发现做出的开创性贡献。
Diabetes Care. 2015 Dec;38(12):2193-9. doi: 10.2337/dc15-0533.

本文引用的文献

1
Selenium and the course of mild Graves' orbitopathy.硒与轻度格雷夫斯眼病的病程。
N Engl J Med. 2011 May 19;364(20):1920-31. doi: 10.1056/NEJMoa1012985.
2
Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.临床综述:静脉内给予糖皮质激素治疗格雷夫斯眼病:疗效和发病率。
J Clin Endocrinol Metab. 2011 Feb;96(2):320-32. doi: 10.1210/jc.2010-1962. Epub 2011 Jan 14.
3
The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy.Graves 病伴发眼眶病患者中如何治疗格雷夫斯甲亢的困境。
J Clin Endocrinol Metab. 2011 Mar;96(3):592-9. doi: 10.1210/jc.2010-2329. Epub 2010 Dec 29.
4
Graves' ophthalmopathy.格雷夫斯眼病。
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
5
Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis.生理膳食硒补充对自身免疫性甲状腺炎自然病程的影响。
Clin Endocrinol (Oxf). 2010 Oct;73(4):535-9. doi: 10.1111/j.1365-2265.2009.03758.x.
6
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy.利妥昔单抗治疗严重、皮质类固醇抵抗的甲状腺相关眼病患者。
Ophthalmology. 2010 Jan;117(1):133-139.e2. doi: 10.1016/j.ophtha.2009.05.029. Epub 2009 Oct 8.
7
Severe hyperthyroidism: aetiology, clinical features and treatment outcome.严重甲状腺功能亢进症:病因、临床特征和治疗结果。
Clin Endocrinol (Oxf). 2010 Apr;72(4):551-7. doi: 10.1111/j.1365-2265.2009.03682.x. Epub 2009 Aug 4.
8
Quality of life and occupational disability in endocrine orbitopathy.内分泌性眼眶病的生活质量与职业残疾
Dtsch Arztebl Int. 2009 Apr;106(17):283-9. doi: 10.3238/arztebl.2009.0283. Epub 2009 Apr 24.
9
Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis.格雷夫斯眼病的治疗方式:系统评价与荟萃分析
J Clin Endocrinol Metab. 2009 Aug;94(8):2708-16. doi: 10.1210/jc.2009-0376. Epub 2009 Jun 2.
10
Thyroid eye disease.甲状腺眼病
BMJ. 2009 Mar 6;338:b560. doi: 10.1136/bmj.b560.